HUTCHMED wins FDA orphan designation for sovleplenib
Key points
- HUTCHMED (NASDAQ:HCM) received US Food and Drug Administration Orphan Drug Designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk.
- The designation provides access to development incentives, and the drug could qualify for seven years of US market exclusivity if approved for the designated indication.
- Sovleplenib applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia are under regulatory review, supported by positive pivotal trial data.
HUTCHMED (NASDAQ:HCM) received US Food and Drug Administration Orphan Drug Designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk.
The designation provides access to development incentives, including potential clinical-trial tax credits, user fee waivers and specialized FDA guidance, while approval could qualify the drug for seven years of US market exclusivity.
Sovleplenib is an oral spleen tyrosine kinase inhibitor that targets an enzyme involved in immune signaling, and HUTCHMED retains all worldwide rights to the drug.
In China, sovleplenib applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia remain under regulatory review, supported by positive pivotal ESLIM-01 and ESLIM-02 trial results, respectively.
The US designation applies to the development of sovleplenib for the designated condition, while any market exclusivity would depend on FDA approval for that indication.
Frequently asked questions
More from United States
California Water Service Q3 revenue increases 6.7% to $332.2 million
Fiverr Q3 revenue falls 15.8% to $90.9 million
ING delivers Q3 net result €1.85 billion, up 3.5%
Molecular Partners plans cuts of up to 44% as focus shifts
STMicroelectronics records 17.9% Q3 revenue increase to $3.76B
AB InBev Q3 revenue jumps 9.1% to $16.51 billion
